Sunday, June 13, 2021
Annovis Bio, Inc. (NYSE American: ANVS) Skyrockets 112% After Phase 2 Clinical Data Shows Significant Cognitive Improvement in Patients With Alzheimer’s Disease
Annovis Bio, Inc. (NYSE American: ANVS) is engaged as a clinical-stage biopharmaceutical company, which focuses on developing treatments for neurodegeneration...
Read more
Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) Jumps 42% After Announcing Merger with Aadi Bioscience, First Quarter 2021 Financial Results
Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) is engaged as a biopharmaceutical company focused on the research and development of activating compounds...
Read more
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) Rallies 60% After Releasing Positive Phase 2 Clinical Trials Data on Treatment of Acute Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is engaged as a clinical-stage biopharmaceutical company that primarily focuses on the research, development,...
Read more
Here’s Why Shares of Humanigen, Inc. (NASDAQ: HGEN) Are Surging 103% on Monday, March 29, 2021
Humanigen, Inc. (NASDAQ: HGEN) is a clinical-stage biotechnology company that is focused on the research and development of cancers, infectious...
Read more
SunLink Health Systems, Inc. (NYSE American: SSY) Surges 180% After Announcing Major $2 Million Expansion and Upgrade at its Trace Regional Hospital
SunLink Health Systems, Inc. (NYSE American: SSY), through its subsidiaries, owns and operates healthcare properties and related businesses in the...
Read more
Entera Bio, Ltd. (NASDAQ: ENTX) Skyrockets 242% After Its Phase 2 Biomarker Data of EB613 Met Primary Endpoint
Entera Bio, Ltd. (NASDAQ: ENTX) is a global leader in the research and development of orally-delivered large molecule therapeutics across...
Read more
Second Sight Medical Products, Inc. (NASDAQ: EYES) Skyrockets 156% After its Argus 2s Retinal Prosthesis System is Approved By FDA
Second Sight Medical Products, Inc. (NASDAQ: EYES) is engaged within the research, development, and marketing of implantable visual prosthetics. The...
Read more
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) Soars 78% After Agreeing to be Acquired by Amgen (NASDAQ: AMGN) for $1.9 Billion
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) is engaged as a clinical stage biotechnology company that is focused on developing novel...
Read more
Entera Bio, Ltd. (NASDAQ: ENTX) Skyrockets 242% After Its Phase 2 Biomarker Data of EB613 Met Primary Endpoint
Entera Bio, Ltd. (NASDAQ: ENTX) is a global leader in the research and development of orally-delivered large molecule therapeutics across...
Read more
Second Sight Medical Products, Inc. (NASDAQ: EYES) Skyrockets 156% After its Argus 2s Retinal Prosthesis System is Approved By FDA
Second Sight Medical Products, Inc. (NASDAQ: EYES) is engaged within the research, development, and marketing of implantable visual prosthetics. The...
Read more
